Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/03/2005CA2563491A1 Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol, and applications thereof
11/03/2005CA2563377A1 Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
11/03/2005CA2563356A1 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
11/03/2005CA2563192A1 Tri(cyclo) substituted amide compounds
11/03/2005CA2563180A1 Non-nucleoside reverse transcriptase inhibitors
11/03/2005CA2562812A1 Imidazopyridine compound
11/03/2005CA2562734A1 Methods of treatment with syk inhibitors
11/03/2005CA2562731A1 Apparatus and method for transdermal delivery of fentanyl-based agents
11/03/2005CA2562673A1 Universal target sequences for sirna gene silencing
11/03/2005CA2562571A1 Novel androgens
11/03/2005CA2562548A1 Expression of fatty acid desaturases in corn
11/03/2005CA2562507A1 Polymorphic forms of methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate hydrobromide, clopidrogel hydrobromide
11/03/2005CA2562417A1 Piperidine derivatives as modulators of chemokine receptor ccr5
11/03/2005CA2562377A1 Novel piperidine substituted diaminothiazoles
11/03/2005CA2562100A1 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof
11/03/2005CA2561724A1 Azaindoles useful as inhibitors of rock and other protein kinases
11/03/2005CA2561553A1 Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
11/03/2005CA2561393A1 Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent
11/03/2005CA2561390A1 Methods and compositions for the treatment of myocardial conditions
11/03/2005CA2561281A1 Pharmaceutical composition comprising a salt of mirtazapine
11/03/2005CA2561146A1 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2-,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine for use in treating hiv infection
11/03/2005CA2561006A1 Clopidogrel salt and polymorphic forms thereof
11/03/2005CA2560969A1 Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
11/03/2005CA2560882A1 Crystalline forms of fexofenadine hydrochloride and processes for their preparation
11/03/2005CA2560042A1 Hmb compositions and uses thereof
11/03/2005CA2559917A1 Compounds as ccri antagonists
11/03/2005CA2559700A1 Benzoxazine for treating respiratory tract diseases
11/03/2005CA2559688A1 Novel alkyne compounds with an mch-antagonistic action and medicaments comprising said compounds
11/03/2005CA2559237A1 Novel alkyne compounds having an mch-antagonistic effect and medicaments containing said compounds
11/03/2005CA2559038A1 Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof
11/03/2005CA2559021A1 Novel alkyne compounds with an mch-antagonistic action and medicaments containing said compounds
11/03/2005CA2558755A1 Novel alkyne compounds having an mch-antagonistic effect, and medicaments containing said compounds
11/03/2005CA2558741A1 Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
11/03/2005CA2553309A1 Method of food intake management
11/03/2005CA2552956A1 An innovative screening method for coronary heart disease and stroke
11/02/2005EP1591529A2 Human CLTA-8 and uses of CTLA-8-related proteins
11/02/2005EP1591525A2 Oligoribonucleotides for the treatment of irritative and/or inflammatory skin symptoms by RNA interference
11/02/2005EP1591524A1 Oligoribonucleotide or peptidic nucleic acid inhibiting function of hepatitis c virus
11/02/2005EP1591451A1 Peptide conjugate
11/02/2005EP1591446A1 Thienopyrimidine compounds and use thereof
11/02/2005EP1591444A1 CCR5 antagonists useful for treating aids
11/02/2005EP1591443A1 Pyrazole derivative
11/02/2005EP1591440A1 Alanines compounds, method of preparing them and their use
11/02/2005EP1591437A2 Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
11/02/2005EP1591143A1 Composition comprising a combination of Calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
11/02/2005EP1591135A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/02/2005EP1591127A1 REGENERATION AND NEOGENESIS OF RETINAL VISUAL CELL WITH Otx2 GENE
11/02/2005EP1591123A1 Uses of naringenin, naringin and salts thereof as expectorants in the treatment of cough, and compositions thereof
11/02/2005EP1591122A1 Method of administering bisphosphonates
11/02/2005EP1591121A1 Steroid hormone products comprising a stabilizing agent in non-crystalline form
11/02/2005EP1591120A1 Receptor agonists
11/02/2005EP1591119A2 Pramipexole for treating CNS diseases, especially Parkinson's disease
11/02/2005EP1591118A1 Use of melatonin in preventing postoperative complications
11/02/2005EP1591117A1 Breast cancer resistance protein (bcrp) inhibitor
11/02/2005EP1591116A1 Inhibitor for perioperative blood sugar elevation
11/02/2005EP1591115A1 Preventive or remedy for intrauterine late embryonic development or pregnancy toxemia
11/02/2005EP1591114A1 Use of metformin and orlistat for the treatment or prevention of obesity
11/02/2005EP1591113A1 Blood pressure-lowering agent, vascular flexibility-improving agent and foods having these functions imparted thereto
11/02/2005EP1591112A1 Breast cancer-resistant protein inhibitor
11/02/2005EP1591109A1 Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
11/02/2005EP1591108A2 Solution formulations of sirolimus and its analogs for CAD treatment
11/02/2005EP1591020A1 Compositions containing coenzyme q10
11/02/2005EP1590668A2 Screeninig and treatment methods for prevention of preterm delivery
11/02/2005EP1590457A2 Oligonucleotides directed against a survivin gene and use thereof
11/02/2005EP1590442A2 Macrocyclic hepatitis c serine protease inhibitors
11/02/2005EP1590430A2 SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA
11/02/2005EP1590357A2 Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses
11/02/2005EP1590345A1 Xanthine derivatives as muscarinic receptor antagonists
11/02/2005EP1590344A2 Anti-cancer medicaments
11/02/2005EP1590340A1 Inhibitors of histone deacetylase
11/02/2005EP1590339A2 Chemical compounds
11/02/2005EP1590335A2 Process for preparing pyrrolotriazine kinase inhibitors
11/02/2005EP1590334A1 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
11/02/2005EP1590333A1 Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof
11/02/2005EP1590328A2 (2-carboxamido) (3-amino) thiophene compounds
11/02/2005EP1590326A2 Substituted alkyl amido piperidines
11/02/2005EP1590321A2 Aryl alkyl carbamate derivatives production and use thereof in therapy
11/02/2005EP1590046A2 Composition for the treatment of hiv or aids
11/02/2005EP1590000A1 Hardenable thermally responsive compositions
11/02/2005EP1589989A2 Osteogenic composition
11/02/2005EP1589980A2 Methods of diagnosis and treatment of interstitial lung disease
11/02/2005EP1589979A2 Compounds for the normalization of the sleep/wake cycle
11/02/2005EP1589978A2 Delivery system for functional compounds
11/02/2005EP1589977A1 Topical ointment for vesicating chemical warfare agents
11/02/2005EP1589976A1 Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis
11/02/2005EP1589975A2 Dehydroepiandrosterone (dhea) congeners for prevention and/or treatment of ulcers
11/02/2005EP1589974A2 Use of n-desmethylclozapine to treat human neuropsychiatric disease
11/02/2005EP1589973A1 Formulation and methods for the treatment of thrombocythemia
11/02/2005EP1589972A1 Benzoquinolizine-2-carboxylic acid-containing compositions
11/02/2005EP1589971A1 Ophthalmic compositions containing loratadine
11/02/2005EP1589970A2 Pharmaceutical compositions comprising thieno [2,3-c]pyridine deritives and use thereof
11/02/2005EP1589969A2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/02/2005EP1589968A2 Quaternary antimuscarinic compounds for the treatment of bladder diseases
11/02/2005EP1589967A1 Benzthiazole-3 oxides useful for the treatment of proliferative disorders
11/02/2005EP1589965A1 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination
11/02/2005EP1589964A1 Compounds having anti-proliferative properties
11/02/2005EP1589963A1 Use of 10-aminoaliphatyl-dibenz b,f oxepines for the tr eatment of degenerative ocular disorders
11/02/2005EP1589962A2 Polyurethanes for osteoimplants
11/02/2005EP1589961A2 A therapeutic composition for the treatment of hiv-1 and hiv-2
11/02/2005EP1589960A1 Treatment of obesity and associated conditions with tgf-beta inhibitors
1 ... 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 ... 7860